Earnings Feed
Start Free
Home/Filings/4/0001192482-13-000246
4//SEC Filing

TETRALOGIC PHARMACEUTICALS CORP 4

Accession 0001192482-13-000246

CIK 0001361248operating
View on SEC.govCompany Profile

Filed

Dec 18, 7:00 PM ET

Accepted

Dec 19, 2:29 PM ET

Size

55.5 KB

Accession

0001192482-13-000246

Insider Transaction Report

Form 4
Period: 2013-12-17
TETRALOGIC PHARMACEUTICALS CORPTLOG
Woody James N.
Director
Transactions
  • Conversion

    Common Stock

    2013-12-17+8,866→ 642,689 total(indirect: See footnotes)
  • Exercise of In-Money

    Common Stock

    2013-12-17$6.40/sh+71$455→ 1,001,988 total(indirect: See footnotes)
  • Conversion

    Series B Convertible Preferred Stock

    2013-12-17−354,663→ 0 total(indirect: See footnotes)
    → Common Stock (354,663 underlying)
  • Conversion

    Common Stock

    2013-12-17$7.00/sh+104,118$728,826→ 991,117 total(indirect: See footnotes)
  • Conversion

    Series B Convertible Preferred Stock

    2013-12-17−17,733→ 0 total(indirect: See footnotes)
    → Common Stock (17,733 underlying)
  • Conversion

    Series B Convertible Preferred Stock

    2013-12-17−8,866→ 0 total(indirect: See footnotes)
    → Common Stock (8,866 underlying)
  • Conversion

    Common Stock

    2013-12-17+11,363→ 881,318 total(indirect: See footnotes)
  • Conversion

    Common Stock

    2013-12-17$7.00/sh+5,205$36,435→ 996,322 total(indirect: See footnotes)
  • Purchase

    Common Stock

    2013-12-17$7.00/sh+243,189$1,702,323→ 243,189 total(indirect: See footnotes)
  • Purchase

    Common Stock

    2013-12-17$7.00/sh+12,159$85,113→ 255,348 total(indirect: See footnotes)
  • Purchase

    Common Stock

    2013-12-17$7.00/sh+6,079$42,553→ 261,427 total(indirect: See footnotes)
  • Conversion

    Common Stock

    2013-12-17+227,266→ 869,955 total(indirect: See footnotes)
  • Exercise of In-Money

    Common Stock

    2013-12-17$6.40/sh+143$916→ 1,001,917 total(indirect: See footnotes)
  • Conversion

    Series C Convertible Preferred Stock

    2013-12-17−5,681→ 0 total(indirect: See footnotes)
    → Common Stock (5,681 underlying)
  • Conversion

    Convertible Notes

    2013-12-17−104,118→ 0 total(indirect: See footnotes)
    Exercise: $7.00→ Common Stock (104,118 underlying)
  • Conversion

    Convertible Notes

    2013-12-17−2,602→ 0 total(indirect: See footnotes)
    Exercise: $7.00→ Common Stock (2,602 underlying)
  • Conversion

    Common Stock

    2013-12-17+354,663→ 616,090 total(indirect: See footnotes)
  • Conversion

    Common Stock

    2013-12-17+17,733→ 633,823 total(indirect: See footnotes)
  • Conversion

    Common Stock

    2013-12-17+5,681→ 886,999 total(indirect: See footnotes)
  • Conversion

    Common Stock

    2013-12-17$7.00/sh+2,602$18,214→ 998,924 total(indirect: See footnotes)
  • Conversion

    Series C Convertible Preferred Stock

    2013-12-17−11,363→ 0 total(indirect: See footnotes)
    → Common Stock (11,363 underlying)
  • Conversion

    Convertible Notes

    2013-12-17−5,205→ 0 total(indirect: See footnotes)
    Exercise: $7.00→ Common Stock (5,205 underlying)
  • Exercise of In-Money

    Series C Warrants

    2013-12-17−2,850→ 0 total(indirect: See footnotes)
    Exercise: $6.40→ Common Stock (2,850 underlying)
  • Exercise of In-Money

    Series C Warrants

    2013-12-17−143→ 0 total(indirect: See footnotes)
    Exercise: $6.40→ Common Stock (143 underlying)
  • Exercise of In-Money

    Series C Warrants

    2013-12-17−71→ 0 total(indirect: See footnotes)
    Exercise: $6.40→ Common Stock (71 underlying)
  • Exercise of In-Money

    Common Stock

    2013-12-17$6.40/sh+2,850$18,246→ 1,001,774 total(indirect: See footnotes)
  • Conversion

    Series C Convertible Preferred Stock

    2013-12-17−227,266→ 0 total(indirect: See footnotes)
    → Common Stock (227,266 underlying)
Footnotes (8)
  • [F1]Directly owned by LVP Life Science Ventures, III, L.P.
  • [F2]Directly owned by LVP III Associates, L.P.
  • [F3]Directly owned by LVP III Partners, L.P.
  • [F4]Shares of Series B Convertible Preferred Stock were automatically converted to the same number of shares of Common Stock at the time of the Company's initial public offering on December 17, 2013.
  • [F5]Shares of Series C Convertible Preferred Stock were automatically converted to the same number of shares of Common Stock at the time of the Company's initial public offering which occurred on December 17, 2013.
  • [F6]The Convertible Notes and Accrued Interest automatically converted into Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering, at the initial public offering price of $7.00 per share, which occurred on December 17, 2013.
  • [F7]The warrants were automatically exercised immediately prior to the closing of the Issuer's initial public offering for a number of shares of common stock equal to the warrant amount divided by $6.4022 and net exercised at the initial public offering price of $7.00 per share.
  • [F8]The reported securities are owned directly by each of LVP Life Science Ventures III, L.P. ("LVP III"), LVP III Associates, L.P. ("Associates"), and LVP III Partners, L.P. ("Partners"). LVP GP III, LLC ("GP III") is the general partner of LVP III, Associates, and Partners. The reporting person, a member of GP III, shares voting and investment power with respect to these shares but disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein

Documents

1 file

Issuer

TETRALOGIC PHARMACEUTICALS CORP

CIK 0001361248

→
Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001361248

Filing Metadata

Form type
4
Filed
Dec 18, 7:00 PM ET
Accepted
Dec 19, 2:29 PM ET
Size
55.5 KB
View on SEC.gov